Contestedabout 14 hours ago

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

Limited convergence at 0%. Sources across 2 tiers disagree on key claims.

4 outlets4 reporting0 claims extracted2 regions

The Lens

China's Innovent Biologics signs drug de...

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

Coverage from 0 left, 3 center, 1 right outlets

Far Left

No coverage

Left

No coverage

Center Left

No coverage

Center

South China Morning Post

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

Reuters

Innovent Biologics, Pfizer strike $10.5 bln cancer drug deal amid China biotech boom - Reuters

Reuters

Exclusive: China works on AI token futures market, sources say, in race with US - Reuters

Center Right

Nikkei Asia

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

Right

No coverage

Far Right

No coverage

Center (3)

South China Morning Post

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

Reuters

Innovent Biologics, Pfizer strike $10.5 bln cancer drug deal amid China biotech boom - Reuters

Reuters

Exclusive: China works on AI token futures market, sources say, in race with US - Reuters

Center Right (1)

Nikkei Asia

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

This analysis is generated automatically from 4 news sources across 2 political bias tiers and 2 global regions. Triangulate does not render editorial judgments.

Triangulate — News Convergence Feed

The Lens

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn